BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to J-82 cell line is 64
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by FACs and IF staining and RT-PCR | NA | 0.56 | 1 | 30397177 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by qRT-PCR | NA | 0.56 | 1 | 35116788 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by FACs | NA | 0.56 | 1 | 31176734 |
| YAP1 | 16262 | HTM/LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by Transcriptomics and RT-PCR and Western Blotting | NA | 0.52 | 0.0117 | 30397177 |
| IL6 | 6018 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by qRT-PCR and ELISA | NA | 0.48 | 0.0191 | 35116788 |
| IL6 | 6018 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.48 | 0.0191 | 30397177 |
| IL6 | 6018 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.48 | 0.0191 | 30397177 |
| OV6 | NA | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by FACs and IF staining | NA | 0.36 | 0.0011 | 30397177 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by FACs and RT-PCR | NA | 0.32 | 0.7582 | 30397177 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by qRT-PCR | NA | 0.32 | 0.7582 | 35116788 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | MACs followed by Tumorigenicity assay | NA | 0.32 | 0.7582 | 24649144 |
| PROM1 | 9454 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by FACs | NA | 0.32 | 0.7582 | 31176734 |
| CCL15 | 10613 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| CCL15 | 10613 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| CCL2 | 10618 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0074 | 30397177 |
| CCL24 | 10623 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| CCL3 | 10627 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| CCL4 | 10630 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| CCL5 | 10632 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0064 | 30397177 |
| CSF1 | 2432 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0032 | 30397177 |
| CSF2 | 2434 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| CSF3 | 2438 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0032 | 30397177 |
| CXCL13 | 10639 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| CXCL9 | 7098 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| ICAM1 | 5344 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0064 | 30397177 |
| IFNG | 5438 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL10 | 5962 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL11 | 5966 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0032 | 30397177 |
| IL12B | 5970 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL12B | 5970 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL13 | 5973 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL15 | 5977 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| IL16 | 5980 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| IL17A | 5981 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL1A | 5991 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0032 | 30397177 |
| IL1B | 5992 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0074 | 30397177 |
| IL1RN | 6000 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0053 | 30397177 |
| IL2 | 6001 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL4 | 6014 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| IL5 | 6016 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL7 | 6023 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| IL8 | 6025 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0159 | 30397177 |
| LTA | 6709 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| PDGFB | 8800 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0032 | 30397177 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | Western Blotting | NA | 0.28 | 0.6448 | 24649144 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.6448 | 35116788 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | J-82 | Cisplatin | RT-PCR | NA | 0.28 | 0.6448 | 26647959 |
| SOX2 | 11195 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | Western Blotting | NA | 0.28 | 0.5695 | 24649144 |
| SOX2 | 11195 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by RT-PCR | NA | 0.28 | 0.5695 | 30397177 |
| SOX4 | 11200 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | Western Blotting | NA | 0.28 | 0.0042 | 26681916 |
| TIMP1 | 11820 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0053 | 30397177 |
| TIMP2 | 11821 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0032 | 30397177 |
| TNF | 11892 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| TNFRSF1A | 11916 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| ABCA2 | 32 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SP assay followed by RT-PCR | NA | 0.2 | 0.0021 | 23226356 |
| ABCB1 | 40 | LTM | Bladder Cancer | Carcinoma | J-82 | Cisplatin | RT-PCR | NA | 0.2 | 0.0604 | 26647959 |
| ABCC1 | 51 | LTM | Bladder Cancer | Carcinoma | J-82 | Cisplatin | RT-PCR | NA | 0.2 | 0.0212 | 26647959 |
| ABCC1 | 51 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SP assay followed by RT-PCR | NA | 0.2 | 0.0212 | 23226356 |
| ABCG2 | 74 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.1739 | 35116788 |
| ABCG2 | 74 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SP assay followed by RT-PCR | NA | 0.2 | 0.1739 | 23226356 |
| KLF4 | 6348 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0891 | 30397177 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.5461 | 35116788 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | J-82 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.5461 | 30397177 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | J-82 | Cisplatin | RT-PCR | NA | 0.2 | 0.5461 | 26647959 |